Tom Saylor has extensive experience in pharmaceutical development, manufacturing and marketing.

• CEO of Sirus, a drug targeting and delivery company, based in Cambridge, England.
• Founder and Chairman, Lotus Healthcare Corporation, an Asian-based integrated pharmaceutical company producing and marketing analgesics, cardiovascular and gastrointestinal products.
• CEO of Cell Systems Limited, a medical applications company in cryopreservation and algal biotechnology.
• Executive Vice President of a multi-billion dollar diversified industrial and financial group based in New York.
• Ministerial appointee in the US administration as a principal negotiator in the Tokyo Round of multilateral trade negotiations.
• Currently a member of the board of Europa-Bio and the executive committee of the British North American Committee.
• Holds an MBA from Harvard University and a BSc from the Georgia Institute of Technology.

Dr. Howell has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas.

• Served in a number of leading roles in the pharmaceutical industry, most recently as Vice President for CMC (Chemistry, Manufacturing & Controls) and Technical Development for BTG.
• Director of Outsourced Manufacturing at UCB-Celltech with responsibilities for the post Proof of Concept (PhIIa through to commercialisation) manufacture and supply of all biological products. Playing a key role in the successful marketing authorisation and launch of CIMZIA™.
• Started her career in API Process Development at GlaxoSmithKline.
• An active member of the BioIndustry Association (BIA) Manufacturing Advisory Committee.
• Has an honours degree in Chemistry from the University of Birmingham and a PhD in Physical Organic Chemistry from the University of St Andrews.

Jan Jezek, the principal inventor of the core protein stabilisation technologies, is a biochemist with a strong background in physical chemistry.

• Currently responsible for R&D activities, platform development and technical IP support in the field of stabilisation of biologics.
• Played a crucial role in the development of stabilising technologies for commercially important proteins that allow preservation of protein structure and biological activity during sterilisation by gamma radiation and during long-term storage at ambient temperature.
• Lead successful grant funded projects with TSB funding.
• Previously a Principal Scientist at Insense Limited, responsible for development of novel medical devices from concept to market.
• Holds a joint Doctorate from the University of Bedfordshire and the University of Chemical technology, Prague.
• Member of the Scientific Advisory Board of the Centre of Excellence in Biopharmaceuticals (University of Manchester).

Dr. Buckler has acquired technical expertise in cell culture and virology over the past 11 years, during her PhD and industrial career.

• Currently responsible for the R&D activities in the virology arena focusing on the formulation process.
• Prior to joining Arecor, Angela was the Team Lead for Vaccine Media Development at Lonza Walkersville, Inc, where she gained experience managing in-house and client projects.
• She has 7 years of industrial experience working with mammalian and insect cell lines, live viruses and live attenuated vaccines.
• Awarded a PhD in Biochemical Engineering from the University of Birmingham.

Guy Casy combines over 18 years’ experience of intellectual property management in pharmaceutical and chemical industries with an extensive background in interdisciplinary science.

• Specialist in planning and implementing IP strategies in technology-oriented businesses .
• Held leadership positions in intellectual property management for Chirotech, Dowpharma and Dow Chemical’s Polyurethanes business.
• Started career in IPM at Chiroscience in 1993 with key role in establishing a system of accountable, cross-functional teams to manage patent portfolios and licenses.
• Awarded a PhD in Organic Synthesis from the University of East Anglia prior to postdoctoral positions at the Universities of Oxford and Bristol.

Dr. Cherif has built up expertise in project management, product development, technology transfer, manufacture and supply across a range of product types in the biotech and therapeutic arena, over her 14 year professional career.

• Currently responsible for managing client projects focusing on biologics formulation and Quality Assurance at Arecor.
• Worked as a Quality Control Manager in the Clinical Trials Manufacturing facility at Xenova Biomanufacturing.
• Managed the antibody production Unit at Inverness Medical Innovations.
• Gained experience in Clinical Biochemistry whilst working at Cambridge University as a Postdoctoral Research Associate.
• Has a PhD in Cell Biology from the Catholic University of Louvain, Belgium, "La Plus Grande Distinction".

Barry joined Arecor in 2007 and is responsible for coordinating all research and platform development to expand the novel formulation stabilisation technology. After studying pharmacology Barry moved towards protein biochemistry and gained extensive knowledge in proteomics and molecular cell biology within a variety of biomedical fields within academia and industry.

• Experienced with analytical protein characterisation, process development and managing project programmes.
• Leading role in the design and implementation of protein formulation and the development of biologics.
• Awarded a D.Phil in Biochemistry and Junior Research Fellowship from the University of Oxford.